Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

Journal Articles

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Ghulam J Mufti, FRCP, FRCPath, MD, Steven Best, PhD, Nicholas Lea, PhD, Lewis R. Silverman, MD, Guillermo Garcia-Manero, MD, Nozar Azarnia, PhD, Francois Wilhelm, MD PhD, Gudrun Goehring, MD

Blood (2014) 124 (21): 3258.

https://doi.org/10.1182/blood.V124.21.3258.3258

Published: 2014

Journal Articles

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Blood (2014) 124 (21): 3259.

https://doi.org/10.1182/blood.V124.21.3259.3259

Published: 2014

Journal Articles

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Blood (2014) 124 (21): 163.

https://doi.org/10.1182/blood.V124.21.163.163

Published: 2014

Journal Articles

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Azra Raza, MD, Benjamin Tycko, M.D., Ph.D., Sangmin Lee, MD, Naomi Galili, Ph.D., Abdullah Ali, Andrew Eisenberger, MD, John G. Mears, MD, Aref Al-Kali, MD, Raoul Tibes, MD, PhD, Gary Spitzer, MD, Francois Wilhelm, MD, PhD., Siddhartha Mukherjee, MD, PhD

Blood (2013) 122 (21): 2745.

https://doi.org/10.1182/blood.V122.21.2745.2745

Published: 2013

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Mark Roschewski, MD, Mohammed Farooqui, DO, Georg Aue, MD, Clifton C. Mo, MD, Janet Valdez, PA, Susan Soto, RN, Patricia Perez-Galan, PhD, Francois Wilhelm, MD, PhD., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1803.

https://doi.org/10.1182/blood.V120.21.1803.1803

Published: 2012

Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2012) 120 (21): 3794.

https://doi.org/10.1182/blood.V120.21.3794.3794

Published: 2012

Journal Articles

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Lakshmikanth Katragadda, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, M.D., Ph.D., Manoj Maniar, PhD, Francois Wilhelm, MD, PhD., Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3606.

https://doi.org/10.1182/blood.V120.21.3606.3606

Published: 2012

Journal Articles

Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival,

Azra Raza, MD, Peter L. Greenberg, MD, Matthew J. Olnes, MD, PhD, Lewis R. Silverman, MD, Francois Wilhelm, MD, PhD.

Blood (2011) 118 (21): 3822.

https://doi.org/10.1182/blood.V118.21.3822.3822

Published: 2011

Journal Articles

Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results,

Rami S. Komrokji, MD, Alan F. List, MD, Francois Wilhelm, MD, PhD., Jeffrey E. Lancet, MD, Azra Raza, MD

Blood (2011) 118 (21): 3797.

https://doi.org/10.1182/blood.V118.21.3797.3797

Published: 2011

Journal Articles

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Alice C Fan, MD, Liwen Xu, PhD, Kunju J Sridhar, PhD, Mai Tran, Prajna Banerjee, PhD, John P. Renschler, Radha Tripuraneni, MD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD, Dean W. Felsher, MD, PhD

Blood (2011) 118 (21): 3808.

https://doi.org/10.1182/blood.V118.21.3808.3808

Published: 2011

Journal Articles

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D., James F. Holland, MD

Blood (2010) 116 (21): 2944.

https://doi.org/10.1182/blood.V116.21.2944.2944

Published: 2010

Journal Articles

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Mahesh Seetharam, MD, Mai Tran, Alice C. Fan, MD, Liwen Xu, PhD, John P. Renschler, Dean W. Felsher, MD, PhD, Kunju Sridhar, PhD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD

Blood (2010) 116 (21): 4010.

https://doi.org/10.1182/blood.V116.21.4010.4010

Published: 2010

NARROW

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival,

Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results,

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only